MiniMed Inc. is petitioning the FDA for clearance to produce and market its continuous subcutaneous glucose sensor. The company hopes for approval in 1998. MiniMed expects to utilize the sensor for a series of products – the first two being a physician diagnostic device and alarm product to warn people with diabetes of dangerously low glucose levels.
MiniMed designed the sensor to be inserted under the skin surface, usually in the abdominal area.
“We are extremely excited about our subcutaneous glucose sensor products. We believe they will be the industry’s first ambulatory continuous sensor systems for monitoring glucose levels for people with diabetes,” says chairman and CEO Alfred E. Mann.